These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30294831)

  • 1. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.
    Bologna-Molina R; Ogawa I; Mosqueda-Taylor A; Takata T; Sánchez-Romero C; Villarroel-Dorrego M; Takeda Y; Mikami T
    Oral Dis; 2019 Mar; 25(2):481-487. PubMed ID: 30294831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features.
    Coura BP; Bernardes VF; de Sousa SF; França JA; Pereira NB; Pontes HAR; Batista AC; da Cruz Perez DE; Albuquerque Junior RLC; de Souza LB; Martins MD; Diniz MG; Gomez RS; Gomes CC
    Mod Pathol; 2019 Jun; 32(6):799-806. PubMed ID: 30643167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
    Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
    Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors.
    Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC
    J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular diagnostics in odontogenic tumors.
    Buettner R; Gültekin SE
    Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):81-85. PubMed ID: 36378285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
    Kumamoto H; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing pathogenic mutations in dental follicles as an attempt to identify early events in odontogenic tumours tumourigenesis.
    Coura BP; de Resende TAC; de Menezes VCB; Bernardes VF; de Sousa SF; Diniz MG; Gomez RS; Gomes CC
    Arch Oral Biol; 2020 May; 113():104523. PubMed ID: 31543246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
    Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
    Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors.
    Guimarães LM; Coura BP; Gomez RS; Gomes CC
    Front Oral Health; 2021; 2():740788. PubMed ID: 35048058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
    Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
    Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation.
    Fujii S; Ishibashi T; Kokura M; Fujimoto T; Matsumoto S; Shidara S; Kurppa KJ; Pape J; Caton J; Morgan PR; Heikinheimo K; Kikuchi A; Jimi E; Kiyoshima T
    J Pathol; 2022 Jan; 256(1):119-133. PubMed ID: 34622442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
    Vandal G; Geiling B; Dankort D
    PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
    Jafari M; Laraqui A; Baba W; Benmokhtar S; Zaitouni SE; Ali AA; Bounaim A; Moujahid M; Tanz R; Mahfoud T; Sbitti Y; Annaz HE; Abi R; Tagajdid MR; Kochri SE; Lahlou IA; Hsaini HE; Belayachi L; Benjouad A; Ichou M; En-Nya A; Ennibi K
    BMC Cancer; 2022 Nov; 22(1):1142. PubMed ID: 36344948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
    Pereira TDSF; de Amorim LSD; Pereira NB; Vitório JG; Duarte-Andrade FF; Guimarães LM; Diniz MG; Gomes CC; Gomez RS
    J Oral Pathol Med; 2019 Nov; 48(10):906-910. PubMed ID: 31310691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.